Plasma somatostatin-like immunoreactivity during growth-hormone-releasing hormone therapy in non-growth-hormone-deficient children.
To date, the effects of long-term growth hormone (GH)-releasing hormone [GHRH(1-29)-NH2] treatment on the plasma concentrations of somatostatin-like immunoreactivity (SLI) remain undefined. In the present study, the effect of GHRH(1-29)-NH2 therapy on plasma SLI levels has been studied in 11 non-GH-deficient children. The pattern of administration was 5 micrograms/kg body weight, given subcutaneously once every day. There was no significant change in plasma SLI levels after bolus injection of GHRH(1-29)-NH2 before and during GHRH(1-29)-NH2 therapy. However, plasma SLI rose in basal plasma and nocturnal sleep after 3 months of GHRH(1-29)-NH2 therapy and remained the same during 6 months of treatment with GHRH(1-29)-NH2. The reason for this finding is uncertain, but an increase in SLI release from the enteroinsular axis is a possible explanation. The association of our findings with the role of the circulating SLI on nutrient homeostasis and the effects of GNRH on growth velocity is discussed.
Arilla
E
E
Departamento de Bioquímica y Biologia Molecular, Facultad de Medicina, Universidad de Alcalá de Henares, España.
Fragoso
J
J
Barrio
R
R
Colás
B
B
Donnay
S
S
Roca
B
B
Hernández
M
M
D001827:Body Height / Q000187:drug effects; D002648:Child; D006130:Growth Disorders / Q000188:drug therapy*; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D006801:Humans; D007279:Injections, Subcutaneous; D011863:Radioimmunoassay; D013004:Somatostatin / Q000097:blood* / Q000276:immunology; D013997:Time Factors
D013004:Somatostatin; D013007:Growth Hormone-Releasing Hormone